Status:

RECRUITING

Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas

Lead Sponsor:

University of Michigan Rogel Cancer Center

Collaborating Sponsors:

Early Detection Research Network

Clinical Genomics Pathology

Conditions:

Colonic Neoplasms

Eligibility:

All Genders

18+ years

Brief Summary

Colon cancer is the second most common cancer in men and women. It is a disease that can be prevented if it is found early. Colonoscopy is still the best screening tool for colon cancer and the polyps...

Detailed Description

In recognition of the fact that novel potential biomarkers are continually being identified and will need to be validated in a rapid, efficient and scientifically rigorous manner, the NCI has made an ...

Eligibility Criteria

Inclusion

  • Willing to sign informed consent
  • Able to physically tolerate removal of up to 60 ml of blood
  • Adults at least 18 years old
  • Willing to collect 1-2 stool samples and prepare a Fecal Immunochemical Test (FIT)
  • Pregnant or nursing women who otherwise meet the eligibility criteria may participate
  • Subjects with one of the following:
  • Colorectal adenocarcinoma-not treated and in colon at time of stool collection (CRC bin)
  • Adenoma-pathologically confirmed adenoma present in colon at time of stool collection (Adenoma Bin)
  • Higher Risk Non-neoplastic Bin
  • Subjects with a personal history of adenomas (confirmed by pathology) with none present on qualifying colonoscopy
  • Subjects with a personal history of CRC (longer than 3 years ago because of exclusion criteria of cancer within last 3 years) with none present at time of qualifying colonoscopy
  • Any family history of CRC (1st degree relative)
  • Current positive screening stool test for blood, for DNA or for both within 12 months with no follow-up intervention.
  • Average Risk, Non-neoplastic Bin
  • No history or current finding of any colorectal neoplasia including CRC, adenomas, sessile serrated adenomas and no family history of CRC.
  • Subjects who had CRC that was successfully treated at least three years ago may be considered eligible for the adenoma bin if their polyps are adenomas and there is no evidence of CRC, or for the higher risk non-neoplastic bin as noted above.
  • Subjects whose screening colonoscopy shows any of these types of polyps may be included in the non-neoplastic or the higher risk non-neoplastic bin if they meet the other criteria noted above.
  • Hyperplastic polyps
  • Benign mucosal polyps
  • Polypoid granulation tissue
  • Prolapsed mucosal polyps
  • Inflammatory polyp
  • Transitional mucosal polyp
  • Lipoma
  • Gangleoneuroma
  • Neuroma
  • Hamartomatous polyp

Exclusion

  • Cancer patients who have had any surgery, radiation, or chemotherapy for their current colorectal cancer prior to collecting the baseline samples
  • History of or clinically active Inflammatory Bowel Disease
  • Known HNPCC or FAP
  • Inability to provide informed consent.
  • Other active malignancy within 3 years of enrollment except any of the following:
  • Squamous cell carcinoma of the skin
  • Basal cell carcinoma of the skin
  • Carcinoma in situ of the cervix, Stages Ia or Ib invasive squamous cell carcinoma of the cervix treated by surgery only. (Excluded if had pelvic radiation)
  • Stage Ia Grade 1 adenocarcinoma of the endometrium treated with surgery
  • Patients on active chemotherapy or radiation treatment for any purpose
  • Known HIV or chronic active viral hepatitis
  • Women who are pregnant
  • CT colonography (virtual colonoscopy) patients

Key Trial Info

Start Date :

August 7 2019

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

March 1 2028

Estimated Enrollment :

1200 Patients enrolled

Trial Details

Trial ID

NCT00843375

Start Date

August 7 2019

End Date

March 1 2028

Last Update

May 8 2025

Active Locations (13)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (13 locations)

1

Cedars-Sinai Medical Center

Los Angeles, California, United States, 90048

2

Carle Cancer Center

Urbana, Illinois, United States, 61801

3

Dana Farber Cancer Institute

Boston, Massachusetts, United States, 02215

4

University of Michigan

Ann Arbor, Michigan, United States, 48109